These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22402948)

  • 1. Yeast as a model to understand mechanisms and consequences of protein modifications by metabolism derived toxic products.
    Tyedmers J
    Exp Clin Endocrinol Diabetes; 2012 Apr; 120(4):179-81. PubMed ID: 22402948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonenzymatic posttranslational protein modifications in ageing.
    Soskić V; Groebe K; Schrattenholz A
    Exp Gerontol; 2008 Apr; 43(4):247-57. PubMed ID: 18215483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The induction of surface beta-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products.
    Mruthinti S; Sood A; Humphrey CL; Swamy-Mruthinti S; Buccafusco JJ
    Neuroscience; 2006 Oct; 142(2):463-73. PubMed ID: 16890367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring inhibitors against the formation of advanced glycation end-products.
    Peng X; Ma J; Chen F; Wang M
    Food Funct; 2011 Jun; 2(6):289-301. PubMed ID: 21779567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells.
    Guimarães EL; Empsen C; Geerts A; van Grunsven LA
    J Hepatol; 2010 Mar; 52(3):389-97. PubMed ID: 20133001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological aspects of non-enzymatic glycosylation].
    Lozins'ka LM; Semchyshyn HM
    Ukr Biokhim Zh (1999); 2012; 84(5):16-37. PubMed ID: 23342632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein glycation in vivo: functional and structural effects on yeast enolase.
    Gomes RA; Oliveira LM; Silva M; Ascenso C; Quintas A; Costa G; Coelho AV; Sousa Silva M; Ferreira AE; Ponces Freire A; Cordeiro C
    Biochem J; 2008 Dec; 416(3):317-26. PubMed ID: 18651835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts".
    Richter T; Münch G; Lüth HJ; Arendt T; Kientsch-Engel R; Stahl P; Fengler D; Kuhla B
    Neurobiol Aging; 2005 Apr; 26(4):465-74. PubMed ID: 15653175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sour side of neurodegenerative disorders: the effects of protein glycation.
    Vicente Miranda H; Outeiro TF
    J Pathol; 2010 May; 221(1):13-25. PubMed ID: 20186922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes.
    Unoki H; Bujo H; Yamagishi S; Takeuchi M; Imaizumi T; Saito Y
    Diabetes Res Clin Pract; 2007 May; 76(2):236-44. PubMed ID: 17097186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
    Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species.
    Niiya Y; Abumiya T; Shichinohe H; Kuroda S; Kikuchi S; Ieko M; Yamagishi S; Takeuchi M; Sato T; Iwasaki Y
    Brain Res; 2006 Sep; 1108(1):179-87. PubMed ID: 16872585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction.
    Aldini G; Dalle-Donne I; Colombo R; Maffei Facino R; Milzani A; Carini M
    ChemMedChem; 2006 Oct; 1(10):1045-58. PubMed ID: 16915603
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases.
    Reddy VP; Beyaz A
    Drug Discov Today; 2006 Jul; 11(13-14):646-54. PubMed ID: 16793534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process: a mini-review.
    Fleming TH; Humpert PM; Nawroth PP; Bierhaus A
    Gerontology; 2011; 57(5):435-43. PubMed ID: 20962515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein glycation in Saccharomyces cerevisiae. Argpyrimidine formation and methylglyoxal catabolism.
    Gomes RA; Sousa Silva M; Vicente Miranda H; Ferreira AE; Cordeiro CA; Freire AP
    FEBS J; 2005 Sep; 272(17):4521-31. PubMed ID: 16128820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylglyoxal, oxidative stress, and hypertension.
    Chang T; Wu L
    Can J Physiol Pharmacol; 2006 Dec; 84(12):1229-38. PubMed ID: 17487230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maillard reaction products in tissue proteins: new products and new perspectives.
    Thorpe SR; Baynes JW
    Amino Acids; 2003 Dec; 25(3-4):275-81. PubMed ID: 14661090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2008 Aug; 71(2):259-61. PubMed ID: 18448262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.